Aug 2026· Cardiovascular Electrophysiology· Vol 37, pp. 2097 - 2111· 0 citations· 43 references
Medicine
TL;DR
LAAC provides similar overall efficacy and safety compared with medical therapy for stroke prevention in AF but should currently remain reserved for selected patients rather than replacing oral anticoagulation broadly, indicating current evidence remains underpowered and additional randomized trials are needed.
Abstract
We aim to compare the impact of left atrial appendage closure vs. medical therapy on clinical outcomes in patients with atrial fibrillation, focusing on key clinical outcomes relevant to thromboembolic prevention. We conducted a PRISMA‐guided systematic review and meta‐analysis of studies comparing LAAC with medical therapy in AF adults. PubMed, Embase, Scopus, ClinicalTrial. gov, and Cochrane Library were searched from inception to March 2026. Outcomes included all‐cause mortality, any stroke, ischemic stroke, hemorrhagic stroke, major bleeding, systemic embolism and cardiac death. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random‐effects models. Reconstructed individual patient‐level survival data from published Kaplan–Meier curves were used for time‐to‐event analyses. Trial sequential analysis (TSA) assessed the conclusiveness of cumulative evidence. Six randomized controlled trials involving 7004 patients were included. LAAC demonstrated comparable outcomes to medical therapy for all‐cause mortality, any stroke, major bleeding, systemic embolism, and cardiac death. There was a non‐significant trend toward increased ischemic stroke and reduced hemorrhagic stroke with LAAC. Reconstructed time‐to‐event analyses showed similar cumulative incidence of stroke and bleeding outcomes over follow‐up. TSA demonstrated that the required information size was not reached for any major endpoint, indicating that current evidence remains underpowered and additional randomized trials are needed. LAAC provides similar overall efficacy and safety compared with medical therapy for stroke prevention in AF but should currently remain reserved for selected patients rather than replacing oral anticoagulation broadly. Further adequately powered trials with longer follow‐up are required.
LAAC provides thromboembolic protection comparable to medical therapy while reducing non-procedural bleeding, and its role as an alternative strategy in selected patients at increased bleeding risk is supported.
G. Di Pietro, Riccardo Improta, E. Bruno et al.· Kardiologia polska· 0 citations
BACKGROUND
Left atrial appendage closure (LAAC) is an alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation, but randomized controlled trials have primarily focused on composite end points, potentially obscuring differences in individual clinical outcomes. We compared the...
Adishwar Rao, V. Ravi, M. Murthi et al.· Circulation: Arrhythmia and...· 0 citations
Objective: To determine the incidence of recurrent ischemic stroke following percutaneous left atrial appendage closure in patients with previous thromboembolic events despite oral anticoagulation. Methods: We conducted a systematic review and meta-analysis of studies of any design reporting ischemic stroke recurrence...
T. Bini, M. Gamardella, Antanas Gasys et al.· Journal of Clinical Medicine· 0 citations
Left atrial appendage closure (LAAC) is a reasonable alternative to oral anticoagulation (OAC) in selected patients with atrial fibrillation (AF). We conducted an updated meta-analysis of RCTs comparing LAAC vs. OAC in patients with AF. The primary efficacy endpoint was a composite of all stroke, systemic embolism, or...
Armaan Otaal, Megan Coylewright, Mohamad A. Alkhouli et al.· American Journal of Cardiolo...· 0 citations
BACKGROUND
Ninety percent of left atrial thrombi in nonvalvular atrial fibrillation arise in the left atrial appendage, which can be occluded percutaneously (left atrial appendage closure [LAAC]). Two 2026 trials (CHAMPION-AF and CLOSURE-AF) more than doubled the available randomized evidence comparing LAAC with oral a...
P. Pekyi-Boateng, A. Mahadevan, S. Frimpong et al.· Stroke· 0 citations
Background The left atrial appendage is the primary source of cardiac thrombi, and prophylactic exclusion during cardiac surgery may reduce thromboembolic risk. However, its benefit in patients without preoperative atrial fibrillation (AF) remains uncertain. Methods We searched PubMed, Web of Science, EMBASE, and the C...
Qing-Chun Song, Xiao-Kang Tu, Zi-Long Zheng et al.· Journal of the American Hear...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.